# Novartis AG (NVS)

Source: https://www.quantisnow.com/company/NVS
Generated: 2026-11-22T20:33:04.427Z

- Ticker: NVS
- Exchange: NYSE
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001114448
- Website: novartis.com

## About

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

## Latest NVS news and filings

- 2026-11-19 12:28 UTC [SEC Form 6-K] [SEC Form 6-K filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-novartis-ag-6799868)
- 2026-11-12 21:37 UTC [SEC Form 6-K] [SEC Form 6-K filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-novartis-ag-6788528)
- 2026-11-09 22:29 UTC [SEC Form FWP] [SEC Form FWP filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-fwp-filed-by-novartis-ag-6782112)
- 2026-11-03 13:02 UTC [FDA Approval for LAMPRENE issued to NOVARTIS](https://www.quantisnow.com/insight/fda-approval-for-lamprene-issued-to-novartis-6768506)
- 2026-10-30 16:59 UTC [Analyst Downgrade] [Novartis AG downgraded by Deutsche Bank](https://www.quantisnow.com/insight/novartis-ag-downgraded-by-deutsche-bank-6764975)
- 2026-10-27 10:08 UTC [SEC Form 6-K] [SEC Form 6-K filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-novartis-ag-6758266)
- 2026-09-10 18:12 UTC [Public Offering] [Big Pharma Setbacks Create a New Wave of Rebound Plays](https://www.quantisnow.com/insight/big-pharma-setbacks-create-a-new-wave-of-rebound-plays-6711396)
- 2026-09-10 12:30 UTC [Analyst Upgrade] [Novartis AG upgraded by HSBC Securities](https://www.quantisnow.com/insight/novartis-ag-upgraded-by-hsbc-securities-6710991)
- 2026-09-10 12:30 UTC [Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market](https://www.quantisnow.com/insight/historic-first-in-ms-treatment-could-reshape-a-multibillion-dollar-therapeutics-6710970)
- 2026-09-09 13:36 UTC [Analyst Coverage Initiated] [RBC Capital Mkts initiated coverage on Novartis AG](https://www.quantisnow.com/insight/rbc-capital-mkts-initiated-coverage-on-novartis-ag-6709686)
- 2026-09-09 12:45 UTC [Analyst Downgrade] [Novartis AG downgraded by Deutsche Bank](https://www.quantisnow.com/insight/novartis-ag-downgraded-by-deutsche-bank-6709509)
- 2026-09-08 10:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-novartis-ag-6707258)
- 2026-09-04 21:22 UTC [SEC Form 6-K] [SEC Form 6-K filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-novartis-ag-6706885)
- 2026-09-01 10:21 UTC [SEC Form 6-K] [SEC Form 6-K filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-novartis-ag-6700389)
- 2026-07-21 10:25 UTC [SEC Form 6-K] [SEC Form 6-K filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-novartis-ag-6643064)
- 2026-06-24 12:30 UTC [The Quest to Repair What Multiple Sclerosis Takes Away](https://www.quantisnow.com/insight/the-quest-to-repair-what-multiple-sclerosis-takes-away-6613657)
- 2026-06-11 11:58 UTC [SEC Form 6-K] [SEC Form 6-K filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-novartis-ag-6598193)
- 2026-04-28 10:21 UTC [SEC Form 6-K] [SEC Form 6-K filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-novartis-ag-6517358)
- 2026-03-18 20:23 UTC [SEC Form 6-K] [SEC Form 6-K filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-novartis-ag-6458149)
- 2026-03-11 12:29 UTC [Analyst Upgrade] [Novartis AG upgraded by Argus with a new price target](https://www.quantisnow.com/insight/novartis-ag-upgraded-by-argus-with-a-new-price-target-6441271)
- 2026-02-27 14:00 UTC [Mergers & Acquisitions] [Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy](https://www.quantisnow.com/insight/novartis-successfully-completes-acquisition-of-avidity-biosciences-strengthening-late-stage-neuroscience-6418098)
- 2026-02-04 21:30 UTC [SEC Form S-8] [SEC Form S-8 filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-novartis-ag-6375541)
- 2026-02-04 11:52 UTC [SEC Form 6-K] [SEC Form 6-K filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-novartis-ag-6374068)
- 2026-02-04 11:51 UTC [SEC Form 6-K] [SEC Form 6-K filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-novartis-ag-6374067)
- 2026-02-04 11:50 UTC [SEC Form IRANNOTICE filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-irannotice-filed-by-novartis-ag-6374064)
- 2026-02-04 11:45 UTC [SEC Form 20-F filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-20-f-filed-by-novartis-ag-6374058)
- 2026-01-27 13:47 UTC [Analyst Coverage Initiated] [Citigroup initiated coverage on Novartis AG](https://www.quantisnow.com/insight/citigroup-initiated-coverage-on-novartis-ag-6361730)
- 2026-01-16 21:45 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-novartis-ag-6352454)
- 2026-01-16 21:45 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-novartis-ag-6352451)
- 2026-01-16 21:45 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-novartis-ag-6352448)
- 2026-01-16 21:45 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-novartis-ag-6352447)
- 2026-01-06 18:39 UTC [Analyst Upgrade] [Novartis AG upgraded by Barclays](https://www.quantisnow.com/insight/novartis-ag-upgraded-by-barclays-6337924)
- 2025-12-17 14:00 UTC [Salesforce's Agentforce Life Sciences Selected by Novartis to Drive More Personalized Customer Engagement Globally](https://www.quantisnow.com/insight/salesforces-agentforce-life-sciences-selected-by-novartis-to-drive-more-6319304)
- 2025-12-08 13:16 UTC [Analyst Upgrade] [Novartis AG upgraded by Analyst](https://www.quantisnow.com/insight/novartis-ag-upgraded-by-analyst-6306299)
- 2025-12-03 15:45 UTC [Analyst Upgrade] [Novartis AG upgraded by Morgan Stanley](https://www.quantisnow.com/insight/novartis-ag-upgraded-by-morgan-stanley-6301127)
- 2025-11-25 13:34 UTC [Analyst Upgrade] [Novartis AG upgraded by BofA Securities](https://www.quantisnow.com/insight/novartis-ag-upgraded-by-bofa-securities-6292959)
- 2025-11-20 13:30 UTC [Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For](https://www.quantisnow.com/insight/remeasuring-biotech-pipelines-the-valuation-signal-investors-have-been-waiting-6288205)
- 2025-11-20 11:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-novartis-ag-6287858)
- 2025-11-05 21:33 UTC [SEC Form 6-K] [SEC Form 6-K filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-novartis-ag-6262950)
- 2025-11-04 01:59 UTC [SEC Form FWP] [SEC Form FWP filed by Novartis AG](https://www.quantisnow.com/insight/sec-form-fwp-filed-by-novartis-ag-6257619)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NVS
- Earnings history: https://www.quantisnow.com/earnings/NVS
- Dividend history: https://www.quantisnow.com/dividends/NVS
- Insider transactions: https://www.quantisnow.com/insiders/NVS
- Options chain: https://www.quantisnow.com/options/NVS
- SEC 8-K filings only: https://www.quantisnow.com/company/NVS/8-k
- RSS and alerts for NVS: https://www.quantisnow.com/docs/rss-feeds.md
